Antithrombotic therapy in left ventricular thrombosis and systemic embolism

Area of Science:

• Cardiology
• Cardiovascular Imaging
• Thrombosis

Background:

• Left ventricular (LV) thrombi contribute significantly to morbidity and mortality.
• They are frequently associated with acute and chronic myocardial infarction (MI), accounting for 25% of cardiogenic emboli.
• Two-dimensional echocardiography is the preferred noninvasive imaging technique for LV thrombi detection.

Purpose of the Study:

• To review the incidence, timing, and risk factors of LV thrombus formation after myocardial infarction.
• To discuss the implications of LV thrombi for systemic embolization.
• To outline current recommendations for the prevention and treatment of LV thrombi.

Main Methods:

• Literature review of studies on LV thrombi.
• Analysis of data regarding LV thrombus formation in different types of myocardial infarction.
• Evaluation of imaging techniques, particularly echocardiography.
• Review of treatment strategies including anticoagulation and thrombolysis.

Main Results:

• LV mural thrombi are found in one-third of Q-wave anterior MIs, but less than 5% of non-Q wave or inferior MIs.
• Over half of LV thrombi form within 48 hours of acute MI, with nearly all forming within a week.
• LV thrombus development carries a risk of systemic embolization.

Conclusions:

• Anticoagulation with heparin and warfarin for at least 3 months is recommended for patients with large anterior MIs and heart failure to prevent LV thrombosis and embolism.
• Thrombolytic therapy does not decrease LV thrombus formation risk.
• Optimal treatment for chronic LV thrombi is not yet established.